International Journal of Healthcare Sciences ISSN 2348-5728 (Online) Vol. 8, Issue 2, pp: (277-290), Month: October 2020 - March 2021, Available at: www.researchpublish.com
Diabetic nephropathy and its therapeutic options: A Review Faruk Yusuf1, Yousif Safaa Aldeen Subhi Al Daghestani1, Manish Kumar1, Indu Melkani1, Dileep Singh Baghel1, Bimlesh Kumar1*, Linu Dash1, Anupriya1, Varimadugu Bhanukirankumar Reddy1, Amrik Singh2, Amarish Kumar Sharma3 1
School of Pharmaceutical Sciences, Lovely Professional University, Punjab, India
2
School of Hotel Management & Tourism, Lovely Professional University, Punjab, India 3
Scool of Bioengineering & Bioscience, Lovely Professional University, Punjab, India
Abstract: Diabetic nephropathy (DN) or diabetic kidney disease means the degeneration of kidney function which can be seen in chronic type 1 and type 2 diabetes mellitus patients. Diabetic nephropathy is the leading cause of chronic renal disease and a major cause of cardiovascular mortality. The development of the disease is known to occur in different type stages and is connected to glycemic and blood pressure control. Although, despite aggressive blood sugar control the prevalence of chronic kidney disease (CKD) I in diabetic people have not been seen in the last two decades: which has now lead to the recognition of new additional factors in the development. The two main risk factors for diabetic nephropathy are hyperglycemia and arterial hypertension, but the genetic susceptibility in both type 1 and type 2 diabetes is of great importance. Other risk factors are smoking, dyslipidemia, proteinuria, glomerular hyperfiltration, and dietary factors. The nutritional station of the patient is a very vital and changeable factor that may influence CKD procedure and the result. It directly comes from the traditional diet choices that the patient makes base on poor nutritional recognition. Dietary management of DN victims is challenging, as the factors of diet overload on the kidney function required to be maintained with malnutrition. The single best evidence-based therapy for diabetic nephropathy is therapy with a RAS-blocking medication. The introduction of antioxidant and anti-inflammatory agents to this field had also added a wealth of knowledge. However, many of these agents are still waiting for well-designed clinical studies to prove their beneficial therapeutic role. Keywords: Diabetic Nephropathy(DN), renal disease, Nano formulation, Diabetes mellitus(DM)
I. INTRODUCTION A. Diabetic Nephropathy and diabetes Kidney disease is associated with increased total mortality and cardiovascular morbimortality in the general population and patients with T2DM (Type 2 diabetes) [47]. The prevalence of DN varies according to ethnicity: it is much higher in African-Americans, Asians, and Native-Americans than in Caucasians. African-Brazilians are very more susceptible to progress to end-stage renal disease(ESRD) than people of European ancestry but they appear to be a similar prevalence of micro or macroalbuminuria [2]. Diabetic nephropathy becomes the main cause of end-stage renal failure in the western part of the world [14]. Part of the most important clinical factor of diabetes is connected to chronic tissue complications. Histological changes in DN are identical in T1DM and T2DM. People with T1DM (Type 1 diabetes) and T2DM have equivalent rates of proteinuria, azotemia and ultimately End-stage kidney disease (ESKD) [44]. This was then estimated to grow to almost 550 million people by the year 2035. [1] The early morphological signs of renal damage include nephromegaly and a modified Doppler, but the degree of damage is best ascertained from proteinuria and GFR (Glomerular filtration rate). The core function of the glomerulus is the GFB (Glomerular Filtration Barrier), which has the unique capacity to selectively filter molecules and proteins by size and charge, thus maintaining the body‘s electrolyte and pH balance and blood homeostasis. [31] Renal disease is a major cause of morbidity and mortality for a patient with insulin-independent diabetes mellitus (IDDM) and is now becoming an increasingly important clinical problem in Non-
Page | 277 Research Publish Journals